Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;31(9):900-908.
doi: 10.18553/jmcp.2025.31.9.900.

Capivasertib cost-effectiveness in treating advanced breast cancer: A US health care perspective

Chijioke Okeke  1   2 , Javeria Khalid  2 , J Douglas Thornton  1   2 , Moosa Tatar  2
Affiliations

Capivasertib cost-effectiveness in treating advanced breast cancer: A US health care perspective

Chijioke Okeke et al. J Manag Care Spec Pharm. 2025 Sep.

Abstract

Background: Capivasertib has gained US Food and Drug Administration approval in combination with a hormonal-based regimen (eg, fulvestrant) for managing hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, with results from the CapiTello-291 trial showing Capivasertib plus fulvestrant to have superior efficacy compared with fulvestrant alone.

Objective: To examine the cost-effectiveness of capivasertib plus fulvestrant vs fulvestrant alone for treating HR+/HER2- advanced breast cancer in the United States from a payer's perspective.

Methods: A Markov model of 708 participants with 3 health states (progression-free, progressive disease, death) from CapiTello-291 trial data was used to compare the costs and efficacy of the two treatment strategies on TreeAge Pro software. This model adopted a willingness-to-pay (WTP) threshold of $100,000 per quality-adjusted life-year (QALY) from a US health care perspective. A 10-year lifetime horizon with a monthly cycle length was used with a 3% discount on costs and utilities derived from previously published resources. To assess our model's uncertainty, multiple one-way sensitivity analyses and probabilistic sensitivity analyses using various distribution ranges of our model parameters were conducted.

Results: In the base model, capivasertib plus fulvestrant treatment was expected to generate an incremental 0.62 QALYs at an incremental cost of $79,117.66, which resulted in an incremental cost-effectiveness ratios of $128,283.61/QALY. Our sensitivity analysis shows that at willingness-to-pay levels of $130,000/QALY and $500,100/QALY, the likelihood of capivasertib plus fulvestrant being cost-effective compared with fulvestrant monotherapy was 50% and 100%, respectively.

Conclusions: The findings from this study suggest that adding capivasertib to fulvestrant treatment is not cost-effective when compared with fulvestrant alone, from the perspective of the US health care system. Considering the notable therapeutic impact that the inclusion of this medication in standard treatment plans can have, it is necessary to engage in more extensive talks and negotiations over the pricing of this newly approved medication.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
A Schematic Diagram of the Decision Tree and the Markov State Transition Model
FIGURE 2
FIGURE 2
Tornado Diagram for the One-Way Sensitivity Analysis
FIGURE 3
FIGURE 3
Two-Way Sensitivity Analysis
FIGURE 4
FIGURE 4
CE Acceptability Curve
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin . 2022;72(1):7-33. doi: 10.3322/caac.21708 - DOI - PubMed
    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Wu Y, Liu X, Maculaitis MC, et al. Financial toxicity among patients with breast cancer during the COVID-19 pandemic in the United States. Cancers (Basel) . 2023;16(1):62. doi: 10.3390/cancers16010062 - DOI - PMC - PubMed
    1. National Institutes of Health; National CancerInstitute . Surveillance, Epidemiology, and End Results Program. Cancer stat facts: Female breast cancer. Accessed February 12, 2024. https://seer.cancer.gov/statfacts/html/
    1. Waks AG, Winer EP. Breast cancer treatment: A review. JAMA . 2019;321(3):288-300. doi: 10.1001/jama.2018.19323 - DOI - PubMed

MeSH terms